TN2009000145A1 - Compositions and methods for modulating c-kit and pdgfr receptors - Google Patents

Compositions and methods for modulating c-kit and pdgfr receptors

Info

Publication number: TN2009000145A1
Authority: TN; Tunisia
Prior art keywords: methods; raf; kit; pdgfr; compounds
Prior art date: 2006-10-20

Application number

TNP2009000145A

Other languages

English (en)

Inventor

Donatella Chianelli

Christopher Cow

Yun He

Songchun Jiang

Xiaolin Li

Xiaodong Liu

Zuosheng Liu

Jon Loren

Valentina Molteni

Juliet Nabakka

Pingda Ren

Taebo Sim

Xiaodong Wang

Shuli You

Original Assignee

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-20

Filing date

2009-04-17

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39027274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000145(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-17 Application filed by Irm Llc filed Critical Irm Llc

2010-10-18 Publication of TN2009000145A1 publication Critical patent/TN2009000145A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Virology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Addiction (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Emergency Medicine (AREA)

TNP2009000145A 2006-10-20 2009-04-17 Compositions and methods for modulating c-kit and pdgfr receptors TN2009000145A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86243006P	2006-10-20	2006-10-20
PCT/US2007/081538 WO2008051757A1 (fr)	2006-10-20	2007-10-16	Compositions et procédés de modulation de récepteurs de c-kit et de facteur de croissance dérivé de plaquettes (pdgfr)

Publications (1)

Publication Number	Publication Date
TN2009000145A1 true TN2009000145A1 (en)	2010-10-18

Family

ID=39027274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000145A TN2009000145A1 (en)	2006-10-20	2009-04-17	Compositions and methods for modulating c-kit and pdgfr receptors

Country Status (25)

Country	Link
US (2)	US7678792B2 (fr)
EP (1)	EP2076513A1 (fr)
JP (1)	JP2010506948A (fr)
KR (1)	KR101079520B1 (fr)
CN (1)	CN101528744A (fr)
AR (1)	AR063343A1 (fr)
AU (1)	AU2007309279B2 (fr)
BR (1)	BRPI0718162A2 (fr)
CA (1)	CA2667010A1 (fr)
CL (1)	CL2007003005A1 (fr)
CO (1)	CO6170361A2 (fr)
CR (1)	CR10717A (fr)
EA (1)	EA200900573A1 (fr)
EC (1)	ECSP099353A (fr)
IL (1)	IL197875A0 (fr)
MA (1)	MA30888B1 (fr)
MX (1)	MX2009004141A (fr)
NI (1)	NI200900061A (fr)
NO (1)	NO20091949L (fr)
PE (1)	PE20081262A1 (fr)
SM (1)	SMP200900027B (fr)
TN (1)	TN2009000145A1 (fr)
TW (1)	TW200825081A (fr)
WO (1)	WO2008051757A1 (fr)
ZA (1)	ZA200902711B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003078448A1 (fr)	2002-03-13	2003-09-25	Signum Biosciences, Inc.	Modulation de la methylation de proteines et du phosphate des phosphoproteines
US7923041B2 (en)	2005-02-03	2011-04-12	Signum Biosciences, Inc.	Compositions and methods for enhancing cognitive function
CA2601777A1 (fr)	2005-02-03	2006-08-10	Signum Biosciences, Inc.	Compositions et procedes pour l'amelioration de la fonction cognitive
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) *	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2009004856A (es)	2006-11-09	2009-06-05	Alcon Res Ltd	Matriz polimerica insoluble en agua para suministro de farmaco.
TWI498115B (zh) *	2007-12-27	2015-09-01	Daiichi Sankyo Co Ltd	咪唑羰基化合物
ATE551342T1 (de) *	2008-02-22	2012-04-15	Irm Llc	Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
AU2009239430B2 (en)	2008-04-21	2015-01-22	Signum Biosciences, Inc.	Compounds, compositions and methods for making the same
FR2930552B1 (fr) *	2008-04-24	2012-10-12	Centre Nat Rech Scient	N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
EA201001847A1 (ru) *	2008-06-11	2011-08-30	Айрм Ллк	Соединения и композиции, применяемые для лечения малярии
US20110200597A1 (en) *	2008-08-05	2011-08-18	George Mason Intellectual Properties, Inc.	Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease
JP5444365B2 (ja) *	2008-10-29	2014-03-19	デシフェラファーマシューティカルズ，エルエルシー	抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質
TW201034675A (en) *	2008-12-18	2010-10-01	Sanofi Aventis	Method for treating macular degeneration
US8674095B2 (en)	2008-12-19	2014-03-18	Afraxis Holdings, Inc.	Compounds for treating neuropsychiatric conditions
SG173610A1 (en) *	2009-02-13	2011-09-29	Fovea Pharmaceuticals Sa	[1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
CN102648200A (zh)	2009-10-09	2012-08-22	亚弗克希斯公司	用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
PH12012501535A1 (en)	2010-01-29	2012-10-22	Boehringer Ingelheim Int	Substituted naphthyridines and their use as syk kinase inhibitors
JP5728499B2 (ja) *	2010-02-05	2015-06-03	アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ	タンパク質キナーゼ阻害剤としての化合物および組成物
EP3763740A1 (fr) *	2011-01-26	2021-01-13	Celldex Therapeutics, Inc.	Anticorps anti-kit et leurs utilisations
HUE032820T2 (en)	2011-04-25	2017-11-28	Usher Iii Initiative Inc	Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
EA024845B1 (ru)	2011-07-26	2016-10-31	Бёрингер Ингельхайм Интернациональ Гмбх	Замещенные хинолины и их применение в качестве лекарственных средств
WO2013049407A2 (fr) *	2011-09-30	2013-04-04	Kineta, Inc	Composés anti-viraux
MA37519B1 (fr)	2012-05-15	2017-03-31	Novartis Ag	Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
WO2013171641A1 (fr)	2012-05-15	2013-11-21	Novartis Ag	Composés et compositions pour l'inhibition de l'activité abl1, abl2 et bcr-abl1
AU2013261130A1 (en)	2012-05-15	2014-10-23	Novartis Ag	Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
CA2871332A1 (fr)	2012-05-15	2013-11-21	Novartis Ag	Derives de benzamide pour inhiber l'activite d'abl1, d'abl2 et de bcr-abl2
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR101652229B1 (ko) *	2012-06-07	2016-08-30	데시페라 파마슈티칼스, 엘엘씨.	증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
RU2681730C2 (ru)	2012-07-25	2019-03-12	Селлдекс Терапьютикс Инк.	Антитела против kit и их применения
US9227976B2 (en)	2012-10-25	2016-01-05	Usher Iii Initiative, Inc.	Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
AU2014302458A1 (en) *	2013-06-26	2015-12-24	Proteostasis Therapeutics, Inc.	Methods of modulating CFTR activity
GB201401886D0 (en)	2014-02-04	2014-03-19	Lytix Biopharma As	Neurodegenerative therapies
CA2942386A1 (fr)	2014-03-13	2015-09-17	Proteostasis Therapeutics, Inc.	Composes, compositions et procedes pour augmenter l'activite du cftr
WO2015138934A1 (fr)	2014-03-13	2015-09-17	Proteostasis Therapeutics, Inc.	Composés, compositions et procédés pour augmenter l'activité cftr
EP3145543A4 (fr)	2014-05-23	2017-12-13	Celldex Therapeutics, Inc.	Traitement des affections associées aux éosinophiles ou aux mastocytes
CA2952862A1 (fr)	2014-06-19	2015-12-23	Proteostasis Therapeutics, Inc.	Composes, compositions et procedes pour augmenter l'activite du cftr
CN105085489B (zh)	2014-11-05	2019-03-01	益方生物科技（上海）有限公司	嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016105477A1 (fr)	2014-12-23	2016-06-30	Proteostasis Therapeutics, Inc	Dérivés d'amides 5-phényl- ou 5-hétéroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique
US10344023B2 (en)	2014-12-23	2019-07-09	Proteostasis Therapeutics, Inc.	Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105484A1 (fr)	2014-12-23	2016-06-30	Proteostasis Therapeutics, Inc.	Dérivés d'amide 5-(hétéro)arylpyrazol-3-carboxylique ou d'amide 1-(hétéro)aryltriazol-4-carboxylique utiles pour le traitement, entre autres, de la fibrose kystique
MA41253A (fr)	2014-12-23	2017-10-31	Proteostasis Therapeutics Inc	Composés, compositions et procédés pour augmenter l'activité du cftr
WO2017019589A1 (fr)	2015-07-24	2017-02-02	Proteostasis Therapeutics, Inc.	Composés, compositions et procédés pour augmenter l'activité du cftr
CN105664178B (zh) *	2015-09-24	2019-08-20	洪健	Syk作为肝纤维化/硬化治疗靶点的应用
NZ741093A (en)	2015-10-06	2022-12-23	Proteostasis Therapeutics Inc	Compounds, compositions, and methods for modulating cftr
CN107286077B (zh) *	2016-04-01	2021-04-02	合肥中科普瑞昇生物医药科技有限公司	一种选择性的c-kit激酶抑制剂
SG11201808682XA (en)	2016-04-07	2018-11-29	Proteostasis Therapeutics Inc	Silicone atoms containing ivacaftor analogues
CA3028966A1 (fr)	2016-06-21	2017-12-28	Proteostasis Therapeutics, Inc.	Composes de phenyle-isoxazole-carboxamide substitues et utilisation connexe pour accroitre l'activite de regulateurs de la conductance transmembranaire de la fibrose kystique
WO2018083635A2 (fr) *	2016-11-04	2018-05-11	Auckland Uniservices Limited	Dérivés hétérocycliques tricycliques et leurs utilisations
EP3601216B1 (fr) *	2017-03-21	2023-10-25	Arbutus Biopharma Corporation	Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant pour le traitement de l'infection au virus hepatitis b
ES2971098T3 (es)	2017-05-12	2024-06-03	Enanta Pharm Inc	Inhibidores de la quinasa 1 que regula la señal de apoptosis y métodos de uso de los mismos
MX2019014343A (es) *	2017-05-30	2020-08-03	Deciphera Pharmaceuticals Inc	Uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-n aftiridin-3-il]-2-fluorofenil]-3-fenilurea y analogos para el tratamiento de canceres asociados con anomalias geneticas en el receptor alfa del factor de crecimiento derivado de plaquetas.
WO2019056990A1 (fr) *	2017-09-20	2019-03-28	浙江海正药业股份有限公司	Dérivé de 1,2-dihydro-1,6-naphtyridine, son procédé de préparation et son application en médecine
HUE067314T2 (hu)	2017-09-22	2024-10-28	Jubilant Epipad LLC	Heterociklusos vegyületek mint PAD gátlók
US11426412B2 (en)	2017-10-18	2022-08-30	Jubilant Epipad LLC	Imidazo-pyridine compounds as PAD inhibitors
EP3707135A1 (fr)	2017-11-06	2020-09-16	Jubilant Prodel LLC	Dérivés de pyrimidine utilisés en tant qu'inhibiteurs de l'activation de pd1/pd-l1
IL274762B2 (en)	2017-11-24	2023-10-01	Jubilant Episcribe Llc	Novel heterocyclic compounds as prmt5 inhibitors
JP7523351B2 (ja)	2018-01-31	2024-07-26	デシフェラ・ファーマシューティカルズ，エルエルシー	肥満細胞症の治療のための併用療法
SG11202007198WA (en)	2018-01-31	2020-08-28	Deciphera Pharmaceuticals Llc	Combination therapy for the treatment of gastrointestinal stromal tumors
EP3765453A1 (fr) *	2018-03-13	2021-01-20	Jubilant Prodel LLC	Composés bicycliques utilisés en tant qu'inhibiteurs de l'interaction/activation de pd1/pd-l1
CN112312905B (zh)	2018-05-02	2024-03-15	英安塔制药有限公司	含四唑的细胞凋亡信号调节激酶1抑制剂及其使用方法
WO2020041417A1 (fr) *	2018-08-22	2020-02-27	Enanta Pharmaceuticals, Inc.	Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant un cycloalkyle et leurs procédés d'utilisation
KR102531596B1 (ko)	2018-09-14	2023-05-11	아비스코 테라퓨틱스 컴퍼니 리미티드	Fgfr억제제, 그 제조 방법 및 용도
WO2020106707A1 (fr)	2018-11-19	2020-05-28	Enanta Pharmaceuticals, Inc.	Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs méthodes d'utilisation
ES2988145T3 (es)	2018-11-26	2024-11-19	Forty Seven Inc	Anticuerpos humanizados contra c-kit
US11466033B2 (en)	2019-03-25	2022-10-11	Enanta Pharmaceuticals, Inc.	Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
EP4013412A1 (fr)	2019-08-12	2022-06-22	Deciphera Pharmaceuticals, LLC	Ripretinib pour le traitement de tumeurs stromales gastro-intestinales
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
JP7580123B2 (ja) *	2019-08-25	2024-11-11	国立大学法人山口大学	血管新生関連疾患の予防又は治療用医薬組成物
LT4084779T (lt)	2019-12-30	2024-11-11	Deciphera Pharmaceuticals, Llc	1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos
IL293866A (en)	2019-12-30	2022-08-01	Deciphera Pharmaceuticals Llc	Compositions of amorphous kinase inhibitors and methods of using them
WO2021202900A1 (fr) *	2020-04-02	2021-10-07	Plexxikon Inc.	Composés de 1,6-naphtyridine et procédés de modulation de csk et leurs indications
KR20230121758A (ko)	2020-11-18	2023-08-21	데시페라 파마슈티칼스, 엘엘씨.	Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
CN115108997A (zh) *	2021-03-22	2022-09-27	南开大学	一类具抑菌活性的磺酰脲类化合物的合成与应用
WO2023050007A1 (fr) *	2021-09-29	2023-04-06	Repare Therapeutics Inc.	Composés n-([(l,3,4-thiadiazolyle) ou (thiazolyle)]-5-substitués)carboxamide (substitué) et leur utilisation pour inhiber la polymérase thêta humaine
AR128440A1 (es)	2022-02-03	2024-05-08	Kinnate Biopharma Inc	Inhibidores de cinasas raf
WO2024039864A1 (fr) *	2022-08-19	2024-02-22	Purdue Research Foundation	Inhibiteurs des interactions protéine-protéine
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors
WO2024069592A1 (fr) *	2022-09-29	2024-04-04	Repare Therapeutics Inc.	Composés de n-([(l, 3,4-thiadiazolyle) substitué en position 5 ou (l,3-thiazolyl)](substitué)carboxamide, compositions pharmaceutiques et procédés de préparation de composés amides et leur utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001292320A1 (en)	2000-10-02	2002-04-15	Tanabe Seiyaku Co., Ltd.	Benzylamine compound, process for producing the same, and intermediate therefor
BRPI0415210A (pt) *	2003-10-08	2006-12-05	Irm Llc	compostos e composições como inibidores de proteìna cinase
JP2008525502A (ja) *	2004-12-23	2008-07-17	デシファラファーマスーティカルズ，エルエルシー	抗炎症薬
EP2942349A1 (fr) *	2004-12-23	2015-11-11	Deciphera Pharmaceuticals, LLC	Modulateurs d'enzymes et traitements
MX2008014618A (es) *	2006-05-15	2008-11-28	Irm Llc	Composiciones y metodos para inhibidores de cinasas del receptor fgf.
US8188113B2 (en) *	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AU2007316417B2 (en) *	2006-11-06	2013-08-22	Tolero Pharmaceuticals, Inc.	Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors

2007
- 2007-10-16 CN CNA2007800390373A patent/CN101528744A/zh active Pending
- 2007-10-16 AU AU2007309279A patent/AU2007309279B2/en not_active Ceased
- 2007-10-16 MX MX2009004141A patent/MX2009004141A/es active IP Right Grant
- 2007-10-16 CA CA002667010A patent/CA2667010A1/fr not_active Abandoned
- 2007-10-16 BR BRPI0718162-0A patent/BRPI0718162A2/pt not_active IP Right Cessation
- 2007-10-16 KR KR1020097008062A patent/KR101079520B1/ko not_active Expired - Fee Related
- 2007-10-16 EA EA200900573A patent/EA200900573A1/ru unknown
- 2007-10-16 WO PCT/US2007/081538 patent/WO2008051757A1/fr not_active Ceased
- 2007-10-16 US US11/873,196 patent/US7678792B2/en not_active Expired - Fee Related
- 2007-10-16 EP EP07844322A patent/EP2076513A1/fr not_active Ceased
- 2007-10-16 JP JP2009533484A patent/JP2010506948A/ja active Pending
- 2007-10-19 CL CL200703005A patent/CL2007003005A1/es unknown
- 2007-10-19 PE PE2007001422A patent/PE20081262A1/es not_active Application Discontinuation
- 2007-10-19 AR ARP070104639A patent/AR063343A1/es unknown
- 2007-10-19 TW TW096139384A patent/TW200825081A/zh unknown
2009
- 2009-03-26 IL IL197875A patent/IL197875A0/en unknown
- 2009-04-16 CR CR10717A patent/CR10717A/es not_active Application Discontinuation
- 2009-04-17 TN TNP2009000145A patent/TN2009000145A1/fr unknown
- 2009-04-17 CO CO09039151A patent/CO6170361A2/es not_active Application Discontinuation
- 2009-04-20 NI NI200900061A patent/NI200900061A/es unknown
- 2009-04-20 SM SM200900027T patent/SMP200900027B/it unknown
- 2009-04-20 ZA ZA200902711A patent/ZA200902711B/xx unknown
- 2009-05-13 MA MA31869A patent/MA30888B1/fr unknown
- 2009-05-19 NO NO20091949A patent/NO20091949L/no not_active Application Discontinuation
- 2009-05-20 EC EC2009009353A patent/ECSP099353A/es unknown
- 2009-12-02 US US12/629,665 patent/US8106068B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7678792B2 (en)	2010-03-16
PE20081262A1 (es)	2008-10-29
CA2667010A1 (fr)	2008-05-02
NI200900061A (es)	2010-03-10
MX2009004141A (es)	2009-05-01
BRPI0718162A2 (pt)	2013-11-26
AR063343A1 (es)	2009-01-21
JP2010506948A (ja)	2010-03-04
AU2007309279A1 (en)	2008-05-02
NO20091949L (no)	2009-05-19
AU2007309279B2 (en)	2011-03-24
SMAP200900027A (it)	2009-07-14
TW200825081A (en)	2008-06-16
US20100081656A1 (en)	2010-04-01
CN101528744A (zh)	2009-09-09
WO2008051757A1 (fr)	2008-05-02
US8106068B2 (en)	2012-01-31
IL197875A0 (en)	2009-12-24
SMP200900027B (it)	2010-01-19
CL2007003005A1 (es)	2008-05-23
KR101079520B1 (ko)	2011-11-03
ZA200902711B (en)	2010-05-26
MA30888B1 (fr)	2009-11-02
US20080176846A1 (en)	2008-07-24
CR10717A (es)	2009-07-02
EP2076513A1 (fr)	2009-07-08
CO6170361A2 (es)	2010-06-18
KR20090054477A (ko)	2009-05-29
EA200900573A1 (ru)	2009-10-30
ECSP099353A (es)	2009-06-30

Publication	Publication Date	Title
TN2009000145A1 (en)	2010-10-18	Compositions and methods for modulating c-kit and pdgfr receptors
MX2010002005A (es)	2010-03-11	Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
TN2010000087A1 (en)	2011-09-26	5-(4- haloalkoxy) phenyl pyrimidine -2- aminecompounds and compositons as kinase inhibitors
TNSN06406A1 (en)	2008-02-22	Compounds and compositions as protein kinase inhibitors
WO2005034869A3 (fr)	2005-07-07	Composes et compositions convenant comme inhibiteurs de proteine-kinases
TW200637547A (en)	2006-11-01	Compounds and compositions as protein kinase inhibitors
MX2008001969A (es)	2008-04-11	Compuestos y composiciones como inhibidores de proteina cinasa.
PL2027123T3 (pl)	2011-09-30	Związki i kompozycje jako inhibitory kinaz białkowych
WO2006124731A3 (fr)	2007-03-29	Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases
MX2009003456A (es)	2009-04-14	Compuestos y composiciones como inhibidores de proteina cinasa.
MX2008002165A (es)	2008-04-29	Compuestos y composiciones como inhibidores de la proteina cinasa.
EA200901654A1 (ru)	2010-06-30	Ингибиторы и способы с их использованием
EA201000003A1 (ru)	2010-06-30	Ингибиторы протеинкиназ и способы их применения
TW200726766A (en)	2007-07-16	Compounds and compositions as protein kinase inhibitors
TNSN07176A1 (en)	2008-11-21	Compounds and compositions as protein kinase inhibitors
WO2005039486A3 (fr)	2006-03-16	Composes et compositions servant d'inhibiteurs de la proteine kinase
BRPI0512422A (pt)	2008-03-04	compostos e composições como inobidores da proteìna quinase
WO2005030151A3 (fr)	2005-09-09	Composes et compositions utiles comme inhibiteurs de la proteine kinase
DOP2009000083A (es)	2009-06-30	Composiciones y metodos para modular recpetores de pdgfr y c-kit
TH98294A (th)	2009-09-17	องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์
TH98294B (th)	2009-09-17	องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์